1043-3155 Pediatr Neurol Briefs pedneurbriefs Pediatr Neurol Briefs Pediatric Neurology Briefs Pediatr Neurol Briefs 2166-6482 1043-3155 2166-3155 Pediatric Neurology Briefs Publishers Chicago, IL, USA PNB-9-66-b 10.15844/pedneurbriefs-9-9-3 Movement Disorders Neurology Pediatrics Nervous System Diseases Child Development Brain Diseases Neurosurgery Child Infant Guanfacine in Comorbid ADHD & Tourette’s Syndrome http://orcid.org/0000-0002-0173-7931 Millichap J. Gordon MD 1 2 * Division of Neurology, Children's Memorial Hospital, Chicago, IL Departments of Pediatrics and Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL Correspondence: Dr. J. Gordon Millichap, E-mail: jgmillichap@northwestern.edu 09 1995 01 06 2016 9 9 66 67 Copyright: © 1995 The Author(s) 1995 This work is licensed under the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience

An open-label study of guanfacine (1.5 mg/d), an a-adrenergic agonist, in 10 children with TS + ADHD, aged 8 to 16 years, was reported from the Yale University School of Medicine, New Haven, CT, and Johns Hopkins Medical Institutions, Baltimore, MD.

 Open-Label Study Commission Errors Phonic Tics

An open-label study of guanfacine (1.5 mg/d), an a-adrenergic agonist, in 10 children with TS + ADHD, aged 8 to 16 years, was reported from the Yale University School of Medicine, New Haven, CT, and Johns Hopkins Medical Institutions, Baltimore, MD. At 4 to 20 weeks follow-up, significant decreases were observed in commission errors and omission errors on Continuous Performance Tests, and the severity of motor and phonic tics was also decreased. Side effects occurred in all patients and included transient fatigue, headaches, insomnia, and sedation. [1]

COMMENT. The authors recommend guanfacine as a safe alternative to stimulants and without the hypotensive or sedative effects of clonidine in the treatment of ADHD complicated by Tourette’s syndrome.

Risperidone, a neuroleptic with both serotonin- and dopamine-blocking properties, reduced tic frequency and intensity in seven children and adolescents with Tourette’s syndrome and chronic motor tic disorders. Weight gain was the most frequent side effect. [2]

 Chappell PB Riddle MA Scahill L Lynch KA Schultz R Arnsten A Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette’s syndrome: preliminary clinical experience J Am Acad Child Adolesc Psychiatry 1995 Sep 34 9 1140 6 7559307 10.1097/00004583-199509000-00010 Lombroso PJ Scahill L King RA Lynch KA Chappell PB Peterson BS Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report J Am Acad Child Adolesc Psychiatry 1995 Sep 34 9 1147 52 7559308 10.1097/00004583-199509000-00011